Syndax Pharmaceuticals
SNDX
84 hedge funds and large institutions have $106M invested in Syndax Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 27 increasing their positions, 20 reducing their positions, and 10 closing their positions.
120% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 10
35% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 20
17% more funds holding
Funds holding: 72 → 84 (+12)
8.48% less ownership
Funds ownership: 69.53% → 61.05% (-8.5%)
14% less call options, than puts
Call options by funds: $387K | Put options by funds: $448K
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
57% less capital invested
Capital invested by funds: $244M → $106M (-$138M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.87M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$1.95M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$1.77M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.58M |
| 5 |
6CM
683 Capital Management
New York
|
+$900K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$19.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.27M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$4.25M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.17M |
| 5 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$1.94M |
SNDX Hedge Fund Activity: Q2 2018 in Review
84 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q2 2018, worth a combined $106M — down 57% from $244M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new SNDX positions and 10 closed out — a net gain of 12 holders — while 27 added to existing stakes and 20 trimmed.
The largest buyer was BlackRock, adding an estimated $3.87M. The largest seller was BVF Inc, cutting an estimated $19.6M.
- 84 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q2 2018, up from 72 in Q1 2018.
- Funds reported $106M of Syndax Pharmaceuticals stock for Q2 2018, down 57% quarter-over-quarter.
- 22 funds opened new Syndax Pharmaceuticals positions in Q2 2018 and 10 closed out, a net change of +12 holders.
- The largest Syndax Pharmaceuticals buyer in Q2 2018 was BlackRock, an estimated $3.87M added.
- The largest Syndax Pharmaceuticals seller in Q2 2018 was BVF Inc, an estimated $19.6M sold.
Based on aggregated 13F filings for Q2 2018.